CLAIMS

We claim:

- A method of preventing ischemic acute renal failure in an individual in need thereof comprising administering a composition comprising a therapeutically effective amount of erythropoietin and a pharmaceutically acceptable carrier.
- 2. A method of treating ischemic acute renal failure in an individual in need of thereof comprising administering a composition comprising a therapeutically effective amount of erythropoietin and a pharmaceutically acceptable carrier.
- 3. A method of preventing harmful cell apoptosis in renal tubular cells, comprising administering a composition comprising a therapeutically effective amount of erythropoietin and a pharmaceutically acceptable carrier.
- 4. A method of stimulating motogenesis and mitogenesis in renal tubular cells comprising administering a composition comprising a therapeutically effective amount of erythropoietin and a pharmaceutically acceptable carrier.
- 5. The method of claim 1 wherein said erythropoietin is recombinant erythropoietin.
- 6. The method of claim 1 wherein said drug composition further comprises a member selected from the group consisting of pharmaceutically acceptable solvents, diluents, excipients, emulsifiers, and stabilizers.
- 7. The method of claim 1 wherein said drug composition is administered systemically.
- 8. The method of claim 7 wherein said drug composition is administered at subpolycythemic doses.

5

10

15

20

25

5

- 9. The method of claim 8 wherein said subpolycythemic doses are administered 2-4 times.
- 10. The method of claim 9 wherein said doses are administered 24 hours apart.
- 11. The method of claim 10 wherein said doses are in the range of 250-350 U/kg body weight of EPO in a pharmacological composition.